Warning letterPosted January 13, 2026
FDA warning letter to LXR Biotech, LLC
CGMP/Dietary Supplement/Adulterated/Misbranded
FDA posted a warning letter to LXR Biotech, LLC on January 13, 2026; the letter is dated December 23, 2025. Subject: CGMP/Dietary Supplement/Adulterated/Misbranded. Issuing office: Human Foods Program.
On the record
- Company
- LXR Biotech, LLC
- Subject
- CGMP/Dietary Supplement/Adulterated/Misbranded
- Issuing office
- Human Foods Program
- Letter dated
- 2025-12-23
- Posted by FDA
- 2026-01-13
- Source
- FDA warning letters ↗
CFR cited
The record cites 3 sections of 21 CFR Part 111.
The full record
An account shows the violations FDA described and each CFR section it cited.
What a warning letter is
A warning letter is FDA's notice to a company that it found significant violations of federal requirements. FDA asks for a written response, normally within 15 working days. The letter is advisory: it states the agency's position and is not a final agency action.
More
Watch LXR Biotech, LLC
A free account shows the last 7 days of every record. Pro adds a watchlist: one email when FDA acts on a company you name.
From FDA warning letters. The record may have changed since it was read.
Approve Suite is not affiliated with FDA, or with LXR Biotech, LLC.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.